

Special Issue

Personalized Therapy of Hormone-Responsive Breast Cancer

Message from the Guest Editors

Breast cancer is the leading malignancy worldwide with 2.26 million new cases diagnosed in 2020 and an increasing incidence. Approximately 70–80% of tumors are hormone-receptor positive and therefore are considered for endocrine therapy. Treatment modalities depend on patients' menopausal status, tumor stage, performance status, and tumor markers. More than 30% of patients in the adjuvant and even more in advanced stages suffer from disease progress due to intrinsic or acquired resistance against endocrine therapy. To overcome treatment failures, including drug discontinuation due to drug-induced toxicity, better prognostic markers—but also new treatment opportunities—are needed. This Special Issue will focus on basic, translational, and clinical studies aiming to improve endocrine therapy by the identification of new and better predictors for personalized treatment decisions and therapeutic approaches, including the selection of multimodal targets, the use of bioinformatic prediction tools, and both mechanistic and clinical investigations to overcome endocrine drug failure in breast cancer.

Guest Editors

Dr. Thomas Mürdter

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology,
Auerbachstr. 112, 70376 Stuttgart, Germany

Dr. Werner Schroth

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology,
Auerbachstrasse 112, 70376 Stuttgart, Germany

Deadline for manuscript submissions

closed (20 October 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/105705

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)